209 related articles for article (PubMed ID: 26960983)
1. MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma.
Filocamo G; Brunetti M; Colaceci F; Sasso R; Tanori M; Pasquali E; Alfonsi R; Mancuso M; Saran A; Lahm A; Di Marcotullio L; Steinkühler C; Pazzaglia S
Mol Cancer Ther; 2016 Jun; 15(6):1177-89. PubMed ID: 26960983
[TBL] [Abstract][Full Text] [Related]
2. Identification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma.
Wei SF; He DH; Zhang SB; Lu Y; Ye X; Fan XZ; Wang H; Wang Q; Liu YQ
Biochem Pharmacol; 2021 Aug; 190():114593. PubMed ID: 33964282
[TBL] [Abstract][Full Text] [Related]
3. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
[TBL] [Abstract][Full Text] [Related]
4. Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.
Chen B; Trang V; Lee A; Williams NS; Wilson AN; Epstein EH; Tang JY; Kim J
Mol Cancer Ther; 2016 May; 15(5):866-76. PubMed ID: 26823493
[TBL] [Abstract][Full Text] [Related]
5. Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
Gordon RE; Zhang L; Peri S; Kuo YM; Du F; Egleston BL; Ng JMY; Andrews AJ; Astsaturov I; Curran T; Yang ZJ
Clin Cancer Res; 2018 Mar; 24(6):1375-1388. PubMed ID: 29437795
[No Abstract] [Full Text] [Related]
6. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
[TBL] [Abstract][Full Text] [Related]
7. Cynanbungeigenin C and D, a pair of novel epimers from Cynanchum bungei, suppress hedgehog pathway-dependent medulloblastoma by blocking signaling at the level of Gli.
Li XY; Zhou LF; Gao LJ; Wei Y; Xu SF; Chen FY; Huang WJ; Tan WF; Ye YP
Cancer Lett; 2018 Apr; 420():195-207. PubMed ID: 29425683
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E1 Inhibits
Wu F; Zhang C; Zhao C; Wu H; Teng Z; Jiang T; Wang Y
Cancer Res; 2020 Jul; 80(13):2818-2832. PubMed ID: 32371475
[TBL] [Abstract][Full Text] [Related]
9. AT-101 inhibits hedgehog pathway activity and cancer growth.
Wang J; Peng Y; Liu Y; Yang J; Huang M; Tan W
Cancer Chemother Pharmacol; 2015 Sep; 76(3):461-9. PubMed ID: 26113054
[TBL] [Abstract][Full Text] [Related]
10. RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism.
Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG
Cancer Lett; 2019 Feb; 442():341-350. PubMed ID: 30447254
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with Hedgehog pathway inhibitors.
Low JA; de Sauvage FJ
J Clin Oncol; 2010 Dec; 28(36):5321-6. PubMed ID: 21041712
[TBL] [Abstract][Full Text] [Related]
12. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.
Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M
FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740
[TBL] [Abstract][Full Text] [Related]
13. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.
Shou Y; Robinson DM; Amakye DD; Rose KL; Cho YJ; Ligon KL; Sharp T; Haider AS; Bandaru R; Ando Y; Geoerger B; Doz F; Ashley DM; Hargrave DR; Casanova M; Tawbi HA; Rodon J; Thomas AL; Mita AC; MacDonald TJ; Kieran MW
Clin Cancer Res; 2015 Feb; 21(3):585-93. PubMed ID: 25473003
[TBL] [Abstract][Full Text] [Related]
14. Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.
Gruber W; Peer E; Elmer DP; Sternberg C; Tesanovic S; Del Burgo P; Coni S; Canettieri G; Neureiter D; Bartz R; Kohlhof H; Vitt D; Aberger F
Int J Cancer; 2018 Mar; 142(5):968-975. PubMed ID: 29055107
[TBL] [Abstract][Full Text] [Related]
15. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier.
Rohner A; Spilker ME; Lam JL; Pascual B; Bartkowski D; Li QJ; Yang AH; Stevens G; Xu M; Wells PA; Planken S; Nair S; Sun S
Mol Cancer Ther; 2012 Jan; 11(1):57-65. PubMed ID: 22084163
[TBL] [Abstract][Full Text] [Related]
16. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of hedgehog signaling pathway inhibitors.
Liu H; Gu D; Xie J
Chin J Cancer; 2011 Jan; 30(1):13-26. PubMed ID: 21192841
[TBL] [Abstract][Full Text] [Related]
18. Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastoma.
Infante P; Malfanti A; Quaglio D; Balducci S; De Martin S; Bufalieri F; Mastrotto F; Basili I; Garofalo M; Lospinoso Severini L; Mori M; Manni I; Moretti M; Nicoletti C; Piaggio G; Caliceti P; Botta B; Ghirga F; Salmaso S; Di Marcotullio L
Cancer Lett; 2021 Feb; 499():220-231. PubMed ID: 33249196
[TBL] [Abstract][Full Text] [Related]
19. Hedgehog pathway inhibition and the race against tumor evolution.
Atwood SX; Chang AL; Oro AE
J Cell Biol; 2012 Oct; 199(2):193-7. PubMed ID: 23071148
[TBL] [Abstract][Full Text] [Related]
20. Smoothened-activating lipids drive resistance to CDK4/6 inhibition in Hedgehog-associated medulloblastoma cells and preclinical models.
Daggubati V; Hochstelter J; Bommireddy A; Choudhury A; Krup AL; Kaur P; Tong P; Li A; Xu L; Reiter JF; Raleigh DR
J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33476305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
